Overview

Company Overview

CytoDyn is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn’s lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.

View Detailed Stock Data

Stock Info

CYDY Symbol
OTCQB Market
Market Cap
Price
Change
Volume
View IR Calendar

Recent Event

CytoDyn Presentations at
CROI 2017
View Press Releases

Recent News